IBRX Q4 2024 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+5333.1% YoY

Gross Profit

$8M100.0% margin

Operating Income

-$69M-919.0% margin

Net Income

-$59M-783.4% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

+23.7%

Cash Flow

Operating Cash Flow

-$85M

Free Cash Flow

-$87M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$383M

Total Liabilities

$871M

Stockholders' Equity

-$489M

Cash & Equivalents

$143M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$139,000	+5333.1%
Gross Profit	$8M	$139,000	+5333.1%
Operating Income	-$69M	-$85M	+18.7%
Net Income	-$59M	-$233M	+74.7%

Revenue Segments

Product

$8M95%

Product and Service, Other

$443,0005%